BACKGROUND: Characteristics and factors influencing viral decay under tenofovir (TDF) and adefovir (ADV) need to be determined in HIV-HBV-coinfected patients. METHODS: This open-label study compared the HBV dynamics in 85 HIV-HBV-coinfected patients initiating an antiretroviral regimen, either including TDF or associated with ADV. The first 6-month change in viral load was analysed using mixed linear models. The adjusted hazards ratio, comparing the rates of undetectable HBV DNA between treatments, was calculated using a Cox proportional hazard model. RESULTS: The HBV DNA decay, adjusted for baseline HBV viral load was more pronounced in patients treated with TDF than with ADV at 12 months (66% versus 53%, P=0.0001). Patients in the TDF group presented a steeper slope of decline at 1.1 (95% confidence interval [CI] 0.9-1.3), compared with 0.8 (95% CI 0.6-1.0) in the ADV group (P=0.036). The mean time to HBV DNA undetectability was 19.3 months (95% CI 16.7-22.0) with TDF and 25.9 months (95% CI 21.1-30.7) with ADV. When adjusted for hepatitis B virus e antigen, HBV DNA and alanine aminotransferase levels at baseline, the influence of treatment on time to HBV DNA undetectability remained in favour of TDF versus ADV (hazard ratio=2.79, 95% CI 1.05-7.40, P=0.039) CONCLUSIONS: TDF influenced more strongly the early-phase HBV DNA kinetics than ADV. This is associated with a sustained antiviral activity in the TDF group, in which patients reached the threshold of HBV undetectability at a faster rate and in a larger proportion than those taking ADV.
BACKGROUND: Characteristics and factors influencing viral decay under tenofovir (TDF) and adefovir (ADV) need to be determined in HIV-HBV-coinfectedpatients. METHODS: This open-label study compared the HBV dynamics in 85 HIV-HBV-coinfectedpatients initiating an antiretroviral regimen, either including TDF or associated with ADV. The first 6-month change in viral load was analysed using mixed linear models. The adjusted hazards ratio, comparing the rates of undetectable HBV DNA between treatments, was calculated using a Cox proportional hazard model. RESULTS: The HBV DNA decay, adjusted for baseline HBV viral load was more pronounced in patients treated with TDF than with ADV at 12 months (66% versus 53%, P=0.0001). Patients in the TDF group presented a steeper slope of decline at 1.1 (95% confidence interval [CI] 0.9-1.3), compared with 0.8 (95% CI 0.6-1.0) in the ADV group (P=0.036). The mean time to HBV DNA undetectability was 19.3 months (95% CI 16.7-22.0) with TDF and 25.9 months (95% CI 21.1-30.7) with ADV. When adjusted for hepatitis B virus e antigen, HBV DNA and alanine aminotransferase levels at baseline, the influence of treatment on time to HBV DNA undetectability remained in favour of TDF versus ADV (hazard ratio=2.79, 95% CI 1.05-7.40, P=0.039) CONCLUSIONS:TDF influenced more strongly the early-phase HBV DNA kinetics than ADV. This is associated with a sustained antiviral activity in the TDF group, in which patients reached the threshold of HBV undetectability at a faster rate and in a larger proportion than those taking ADV.
Authors: N Tran; R Berne; R Chann; M Gauthier; D Martin; M-A Armand; A Ollivet; C G Teo; S Ijaz; D Flichman; M Brunetto; K P Bielawski; C Pichoud; F Zoulim; G Vernet Journal: J Clin Microbiol Date: 2006-08 Impact factor: 5.948
Authors: Marion G Peters; Janet Andersen; Patrick Lynch; Tun Liu; Beverly Alston-Smith; Carol L Brosgart; Jeffrey M Jacobson; Victoria A Johnson; Richard B Pollard; James F Rooney; Kenneth E Sherman; Susan Swindells; Bruce Polsky Journal: Hepatology Date: 2006-11 Impact factor: 17.425
Authors: Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary Goodman; Jia Ma; Carol L Brosgart; Katyna Borroto-Esoda; Sarah Arterburn; Steven L Chuck Journal: Gastroenterology Date: 2006-09-20 Impact factor: 22.682
Authors: Man-Fung Yuen; Daniel Yee-Tak Fong; Danny Ka-Ho Wong; John Chi-Hang Yuen; James Fung; Ching-Lung Lai Journal: Hepatology Date: 2007-12 Impact factor: 17.425
Authors: Ching-Lung Lai; Edward Gane; Yun-Fan Liaw; Chao-Wei Hsu; Satawat Thongsawat; Yuming Wang; Yagang Chen; E Jenny Heathcote; Jens Rasenack; Natalie Bzowej; Nikolai V Naoumov; Adrian M Di Bisceglie; Stefan Zeuzem; Young Myoung Moon; Zachary Goodman; George Chao; Barbara Fielman Constance; Nathaniel A Brown Journal: N Engl J Med Date: 2007-12-20 Impact factor: 91.245
Authors: Henry L Y Chan; E Jenny Heathcote; Patrick Marcellin; Ching-Lung Lai; Mong Cho; Young M Moon; You-Chen Chao; Robert P Myers; Gerald Y Minuk; Lennox Jeffers; William Sievert; Natalie Bzowej; George Harb; Ralf Kaiser; Xin-Jian Qiao; Nathaniel A Brown Journal: Ann Intern Med Date: 2007-10-01 Impact factor: 25.391
Authors: Knud Schewe; Christian Noah; Hüseyin Sirma; Stefan Schmiedel; Jan Van Lunzen; Jürgen Kurt Rockstroh; Oliver Schildgen Journal: Viruses Date: 2010-07-29 Impact factor: 5.818
Authors: Huw Price; David Dunn; Deenan Pillay; Firouze Bani-Sadr; Theodora de Vries-Sluijs; Mamta K Jain; Noriyoshi Kuzushita; Stefan Mauss; Marina Núñez; Reto Nüesch; Marion Peters; Thomas Reiberger; Christoph Stephan; Lionel Tan; Richard Gilson Journal: PLoS One Date: 2013-07-10 Impact factor: 3.240